Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 1819-1822, May 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alhonen-Hongisto, L.
Right arrow Articles by Marton, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alhonen-Hongisto, L.
Right arrow Articles by Marton, L. J.

Time Dependence of the Potentiation of 1,3-Bis(2-chloroethyl)-1-nitrosourea Cytotoxicity Caused by {alpha}-Difluoromethylornithine-induced Polyamine Depletion in 9L Rat Brain Tumor Cells1

Leena Alhonen-Hongisto2, Dennis F. Deen and Laurence J. Marton3

Brain Tumor Research Center of the Department of Neurological Surgery [L. A-H., D. F. D., L. J. M.] and the Departments of Radiation Oncology [D. F. D.] and Laboratory Medicine [L. J. M.], School of Medicine, University of California, San Francisco, California 94143

Treatment of 9L rat brain tumor cells with 1.0 mM {alpha}-difluoromethylornithine (DFMO) produced a time-dependent depletion of cellular putrescine and spermidine. An increase in the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) cytotoxicity, measured with a colony-forming efficiency assay, followed the time course of polyamine depletion, reaching its maximum at 48 hr, the time at which maximum polyamine depletion was achieved.

Treatment with DFMO at concentrations as low as 0.05 mM for 48 hr effectively depleted putrescine and spermidine and potentiated BCNU cytotoxicity. Treatment for 96 hr with 0.01 mM DFMO produced a partial decrease in putrescine and spermidine levels and a moderate potentiation of BCNU cytotoxicity. The amount of polyamine depletion in 9L cells treated with 0.05, 0.1, and 0.5 mM DFMO was identical at both 48 and 96 hr, but potentiation of BCNU cytotoxicity was greater at 96 hr than at 48 hr.

When 9L cells were treated for 48 hr with 1 mM DFMO and DFMO was then removed from the cultures, polyamine levels did not reach control levels by 96 hr after change of medium. The potentiation of BCNU cytotoxicity during this 96-hr period correlated with the extent of polyamine depletion. When 100 µM putrescine was added to the culture medium after DFMO pretreatment (1 mM), polyamine levels approached those of control cells by 24 hr, and the amount of potentiation of DFMO cytotoxicity decreased. These results show that potentiation of BCNU cytotoxicity correlates closely with the amount of DFMO-induced polyamine depletion in 9L cells.

1 Supported by NIH Grant CA-13525 and the Phi Beta Psi sorority.

2 Recipient of a travel grant from the National Research Council for Natural Sciences (Academy of Finland).

3 To whom requests for reprints should be addressed, at Department of Laboratory Medicine, L-518, University of California, San Francisco, CA 94143.

Received 11/ 7/83. Accepted 2/ 7/84.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
V. A. Levin, K. R. Hess, A. Choucair, P. J. Flynn, K. A. Jaeckle, A. P. Kyritsis, W. K. A. Yung, M. D. Prados, J. M. Bruner, S. Ictech, et al.
Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination {alpha}-Difluoromethylornithine-PCV versus PCV for Anaplastic Gliomas
Clin. Cancer Res., March 1, 2003; 9(3): 981 - 990.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. P. Carbone, J. A. Douglas, J. Thomas, K. Tutsch, M. Pomplun, M. Hamielec, and D. Pauk
Bioavailability Study of Oral Liquid and Tablet Forms of {{alpha}}-Difluoromethylornithine
Clin. Cancer Res., October 1, 2000; 6(10): 3850 - 3854.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
V. A. Levin, J. H. Uhm, K. A. Jaeckle, A. Choucair, P. J. Flynn, W. K. A. Yung, M. D. Prados, J. M. Bruner, S. M. Chang, A. P. Kyritsis, et al.
Phase III Randomized Study of Postradiotherapy Chemotherapy with {{alpha}}-Difluoromethylornithine-Procarbazine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosurea, Vincristine (DFMO-PCV) Versus PCV for Glioblastoma Multiforme
Clin. Cancer Res., October 1, 2000; 6(10): 3878 - 3884.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.